HOME >> MEDICINE >> NEWS
Drug therapy can reduce preterm births and decrease lifetime medical costs

Researchers from MetroHealth Medical Center and Case Western Reserve University in Cleveland, OH found that treating expectant mothers who have had previous spontaneous preterm births with 17 Alpha Hydroxyprogesterone caproate (17P) and reducing the incidence of another preterm birth would consequently reduce both short-term and lifetime medical costs in offspring by $2 billion per year. The results of their study are reported in the March issue of the American Journal of Obstetrics & Gynecology.

"In the United States, preterm birth is the leading cause of neonatal deaths and the leading cause of pediatric neuro-developmental disability, including cerebral palsy and mental retardation. It is also an important cause of chronic lung disease, visual impairment, and other chronic illness in children." That statement, from an editorial authored by Joanne Armstrong, MD, MPH, of Baylor College of Medicine in Houston, TX, and Senior Medical Director, Women's Health for Aetna, also appears in the March issue of the American Journal of Obstetrics & Gynecology. It reinforces why the results of the study are particularly significant.

Combining data from six studies of the costs of preterm births with estimates of the effectiveness of 17P in seven other studies, the investigators determined that initial neonatal hospital costs could be reduced by $3800 per woman treated and could lead to a reduction in lifetime medical costs of $15,900 per child. Senior investigator Jennifer Bailit MD, MPH, of the MetroHealth Medical Center states, "If the eligible population was universally treated with 17P, discounted lifetime medical costs of their offspring could be reduced by more than $2 billion annually. The potential societal savings from Medicaid coverage of 17P are substantial."

Dr. Armstrong continues in the editorial, "As more evidence accumulates about the effectiveness of 17P to prevent preterm birth, the current work of Bailit and colleagues provi
'"/>

Contact: Pamela Poppalardo
ajogmedia@elsevier.com
212-633-3944
Elsevier Health Sciences
26-Apr-2007


Page: 1 2

Related medicine news :

1. Chemotherapy with bevacizumab increases risk of blood clots in arteries
2. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
3. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
4. Hormone therapy offers new hope for ovarian cancer patients
5. Borderline personality disorder shows improvements with intensive psychotherapy
6. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
7. Chemotherapy may enhance the effectiveness of brain tumor vaccines
8. Brain-boosting pill alleviates post-chemotherapy fogginess
9. Adding radioimmunotherapy to chemo may help patients with lymphoma
10. Pre-operative chemotherapy does not increase survival rates for nonsmall cell lung cancer
11. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients

Post Your Comments:
(Date:6/19/2013)... The Cancer Support Community (CSC), an international ... for the whole patient with the launch today of ... This inaugural event, held at the Newseum, will feature ... of Congress members who have made a significant impact ... families currently engaged in the cancer journey. ...
(Date:6/19/2013)... Arem Wellness was developed and is managed ... Ridha Arem, who is determined to help educate the ... Arem Wellness provides a monthly newsletter, a blog, many ... well as an exceptional supplement line uniquely designed by ... role diet and nutrition have not only on ...
(Date:6/19/2013)... to the head; a swift jarring to the body and ... It’s understandable, but what else may follow a concussion injury? ... According to mayoclinic.com , usual symptoms that accompany ... other symptoms may follow, sometimes not for days or weeks ... dizziness, feeling like you’re in a fog, light or noise ...
(Date:6/19/2013)... OR (PRWEB) June 19, 2013 To survive when ... Pilot and Vietnam veteran Captain W.S. “Bud” Orr, the most important ... Speaking to host Sharon Kleyne on the Sharon Kleyne Hour Power ... kit in Vietnam, he always placed extra water ahead of guns ... weight limit on survival kits that pilots could carry on planes ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 ... of an Abbreviated New Drug Application (ANDA) for Hydroxyprogesterone ... generic version of Bristol-Myers Squibb’s drug fomerly known as ... to varied inquiries regarding the anticipated approval and market ... product. , Regarding the status of our pending ANDA, ...
Breaking Medicine News(10 mins):Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3Health News:Arem Wellness Announces a Recipe Contest 2Health News:Arem Wellness Announces a Recipe Contest 3Health News:Concussions Can Lead to Much More Than a Headache, According to MMTR Health Inc. Founder, Terry Moore, Neuromuscular and Cardiovascular Physiologist 2Health News:Vietnam Navy Pilot Reveals to Radio Host Sharon Kleyne That He Carried Extra Water Not a Gun in Survival Kit 2Health News:Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP 2
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- In its first major ... company dedicated to advancing development of the ... release drug therapies in patient disease populations ... the acquisition of Enzon Pharmaceutical,s PEGylation Linker ... product pipeline. Acquisition of this technology will ...
(Date:6/19/2013)... , June 19, 2013 Pharma ... new infographic summary of the results from an ... third of all respondents stated that CROs would be an ... of respondents will be running 6 or more clinical trials ... the Clinical Trial Supply USA Summit ...
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... today that VPII Escrow Corp., a newly formed wholly ... offer of approximately $3.2 billion aggregate principal amount of ... due in 2021 and in 2023, with final tranching ... use the net proceeds from the offering, together with ...
Breaking Medicine Technology:Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
Cached News: